NIH Tetramer Core Facility

The NIH Tetramer Facility is supported by contract HHSN272201300006C from the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health in the Department of Health and Human Services.

COVID-19: STATUS OF THE NIH TETRAMER CORE FACILITY

Emory University, like many other academic institutions, has decided to limit research activity to essential work only in response to the COVID-19 pandemic. As a result of this and discussions with the Director of Yerkes National Primate Research Center and our NIH Program Officers, the TCF will immediately stop taking requests for new reagents and will discontinue work on currently approved reagent requests.

We will make two exceptions to this policy for critical reagent production:

• COVID-19/SARS-CoV-2 related research.
• Ongoing research projects where the loss of TCF reagents would be catastrophic (such as large, in progress human or primate studies) and samples cannot be preserved for future analysis.

If you have a current, approved request for reagents that meets one of the above criteria, you should:

• Compose an email to NIAIDTCFrequest@mail.nih.gov – if you are not the PI, make sure to provide your PI’s name and institution, and include their email address in the cc.
• Describe your need for critical reagent production and how it meets one of the above criteria. If non-COVID-19/SARS-CoV-2 related, provide details for why samples cannot be preserved for future analysis.
• Describe the status of research at your institution and any exemptions that your lab may have to continue laboratory research activities.
• Include the approved allele and peptide/ligand requested and the task order number(s) you were assigned.

If you want to make a new request for reagents that meets one of the above criteria, you should:

• Compose an email to NIAIDTCFrequest@mail.nih.gov – if you are not the PI, make sure to provide your PI’s name and institution, and include their email address in the cc.
• Describe your need for critical reagent production and how it meets one of the above criteria. If non-COVID-19/SARS-CoV-2 related, provide detail for why samples cannot be preserved for future analysis.
• Describe the status of research at your institution and any exemptions that your lab may have to continue laboratory research activities.
• Include the allele and peptide/ligand you intend to request.
• If your request is tentatively approved for critical reagent production, you will receive a link to an online request form by email.

We ask that you share this information with any collaborators that may not have received this information directly. Thanks for your understanding and we will be in contact again when we resume normal operations.